US$37.27+0.1%11月13日 收盘
数据截至2026年9月30日，来自2026年11月13日提交的10-Q
Just reported
From Nektar Therapeutics's results release of 2026年11月12日; its quarterly report has since been filed.
Actual
US$9.4M
-20% y/y
-7.4% q/q
Guided
—
No guide given
Actual
-US$1.63
Guided
—
No guide given
Actual
-US$57.8M
| 指标 | 截至该日的 3 个月2026年9月30日 | 截至该日的 3 个月2025年9月30日 | 变动 |
|---|---|---|---|
| 营业收入合计 | US$9.4M | US$11.8M | -20.39% |
| 利润 | -US$55.7M | -US$35.5M | -56.67% |
| 每股收益 | -US$1.63 | -US$1.87 | +12.83% |
| 自由现金流 | -US$72.3M | -US$48.9M | -47.99% |
这些是单季度数字，不是滚动一年——本站其他地方的数字覆盖十二个月，会大得多。季节性业务在两者之间摆动很大：ServiceNow 在十二月季度赚 20 亿美元自由现金流，在六月季度只有 5 亿。
对比对象是去年同一季度，而不是分析师预测。要说“超预期”或“不及预期”需要一致预期数据，那是我们没有的授权数据——而搞错它比不提更糟。
Nektar Therapeutics reported on 2026年11月12日. We are fetching the call transcript; its summary follows once the transcript is in.
“Exhibit 99.1 Nektar Therapeutics Announces Third Quarter 2026 Financial Results SAN FRANCISCO, November 12, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced its financial results for the third quarter ended September 30, 2026, and provided a business update. Cash and investments in marketable securities on September 30, 2026, were $952.9 million as compared to $245.8 million on December 31, 2025. “This was a pivotal quarter for Nektar as we moved rezpegaldesleukin quickly into Phase 3 development,”
逐字引自公告，且只在文件将其归于具名人士时才展示。
公告在开盘前或收盘后发布，因此区间从公告日前一个交易日的收盘价到公告日之后那个交易日的收盘价——无论哪种情况，反应都包含在内。
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar’s lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus. Nektar’s pipeline also includes preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar is headquartered in San Francisco, California.
公司自己的描述，取自公告末尾。
引述和公司简介来自 Nektar Therapeutics 于 2026年11月12日 提交的第 2.02 项 8-K 文件；表格根据其季度报告编制。 在 EDGAR 上阅读公告 股价已按拆股和分红复权。
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.